Efficacy and safety of simplified follitropin delta dosing in women undergoing intrauterine insemination in Indonesia

Binarwan Halim, Hilma P. Lubis, Carine A. Widjaja

Abstract

Available evidence indicate that Intrauterine Insemination (IUI) cycles with controlled ovarian stimulation (COS) yield better oocyte quality and higher pregnancy rates compared to those without COS in infertile women. As follitropin delta is an improved version of recombinant FSH, its ability to stimulate the development of multiple ovarian follicles is supposedly superior to follitropin alfa. The objective of this study was to evaluate the efficacy and safety of follitropin delta with a simplified dosage equivalent method in Indonesian women undergoing IUI. The design of this study was a retrospective observational study conducted from February 2022 to December 2023 involving 248 IUI cycles at Halim Fertility Center (HFC) IVF Center, Indonesia. Controlled Ovarian Stimulation was performed with follitropin delta with a simplified dosage equivalent method in IUI. From this study, we found that the clinical pregnancy rate (CPR) for IUI was 27.8%. The Ovarian Hyperstimulation Syndrome (OHSS) rates was 0.4%, with 2,9% multiple pregnancies in the follitropin delta with a simplified dosage equivalent method. This study showed no statistically significant differences in pregnancy rates based on age groups and BMI (p=0.288 vs p=0.934). WE conclude that follitropin delta may improve the outcome of intrauterine insemination in women undergoing IUI.

Full Text:

PDF

References

Ombelet W. WHO fact sheet on infertility gives hope to

millions of infertile couples worldwide. Facts, views

Vis ObGyn. 2020;12(4):249–51. Available from:

http://www.ncbi.nlm.nih.gov/pubmed/33575673%0

Ahttp://www.pubmedcentral.nih.gov/articlerender.fc

gi?artid=PMC7863696

ESHRE. Factsheet on infertility – prevalence, treatment

and fertility decline in Europe. 2021;(July):1–2.

Duran HE, Morshedi M, Kruger T and Oehninger S.

Intrauterine insemination: a systematic review on

determinants of success. Hum Reprod Update.

;8(4):373–84.

Available

https://pubmed.ncbi.nlm.nih.gov/12206471/

Immediata V, Patrizio P, Parisen Toldin MR, Morenghi E,

Ronchetti C, Cirillo F, Baggiani A, Albani E and

Levi-Setti PE Twenty-one year experience with

intrauterine inseminations after controlled ovarian

stimulation with gonadotropins: maternal age is the

only prognostic factor for success. J Assist Reprod

Genet. 2020;37(5):1195–201.

Bensdorp AJ, Tjon-Kon-Fat RI, Bossuyt PMM, Koks

CAM, Oosterhuis GJE, Hoek A, Hompes PG,

Broekmans FJ, Verhoeve HR, de Bruin JP, van Golde

R, Repping S, Cohlen BJ, Lambers MD, van Bommel

PF, Slappendel E, Perquin D, Smeenk JM, Pelinck

MJ, Gianotten J, Hoozemans DA, Maas JW,

Eijkemans MJ, van der Veen F, Mol BW and van

Wely M Prevention of multiple pregnancies in

couples with unexplained or mild male subfertility:

randomised controlled trial of in vitro fertilisation

with single embryo transfer or in vitro fertilisation in

modified natural cycle compared with intrauterine

insemination

with

controlled

hyperstimulation. BMJ. 2015;350:g7771. Available

from:

https://pmc.ncbi.nlm.nih.gov/articles/PMC4288434/

Farquhar CM, Liu E, Armstrong S, Arroll N, Lensen S and

Brown J. Intrauterine insemination with ovarian

stimulation versus expectant management for

unexplained infertility (TUI): a pragmatic, open

label, randomised, controlled, two-centre trial.

Lancet. 2018;391(10119):441–50. Available from:

http://www.thelancet.com/article/S01406736173240

/fulltext

Olsson H, Sandström R and Grundemar L. Different

pharmacokinetic and pharmacodynamic properties of

recombinant follicle-stimulating hormone (rFSH)

derived from a human cell line compared with rFSH

from a non-human cell line. J Clin Pharmacol.

;54(11):1299–307.

Available

https://pubmed.ncbi.nlm.nih.gov/24800998/

from:

Koechling W, Plaksin D, Croston GE, Jeppesen J V.,

Macklon KT and Andersen CY. Comparative

pharmacology of a new recombinant FSH expressed

by a human cell line. Endocr Connect.

;6(5):297–305.

Available

https://pubmed.ncbi.nlm.nih.gov/28450423/

from:

Nyboe Andersen A, Nelson SM, Fauser BCJM, García

Velasco JA, Klein BM, Arce JC. Individualized

versus conventional ovarian stimulation for in vitro

fertilization: a multicenter, randomized, controlled,

assessor-blinded, phase 3 noninferiority trial. Fertil

Steril. 2017;107(2):387-396.e4. Available from:

https://pubmed.ncbi.nlm.nih.gov/27912901/

Bosch E, Havelock J, Martin FS, Rasmussen BB, Klein

BM, Mannaerts B, and Arce JC Follitropin delta in

repeated ovarian stimulation for IVF: a controlled,

assessor-blind Phase 3 safety trial. Reprod Biomed

Online. 2019;38(2):195–205. Available from:

https://pubmed.ncbi.nlm.nih.gov/30594482/

from:

ovarian

Qiao J, Zhang Y, Liang X, Ho T, Huang HY, Kim SH,

Goethberg M, Mannaerts B and Arce JC. A

randomised controlled trial to clinically validate

follitropin delta in its individualised dosing regimen

for ovarian stimulation in Asian IVF/ICSI patients.

Hum Reprod. 2021;36(9):2452–62. Available from:

https://pubmed.ncbi.nlm.nih.gov/34179971/

Bissonnette F, Minano Masip J, Kadoch IJ, Librach C,

Sampalis J and Yuzpe A. Individualized ovarian

stimulation for in vitro fertilization: a multicenter,

open label, exploratory study with a mixed protocol

of follitropin delta and highly purified human

menopausal

gonadotropin.

;115(4):991–1000.

Fertil

Available

Steril.

from:

https://pubmed.ncbi.nlm.nih.gov/33267959/

Ishihara O and Arce JC. Individualized follitropin delta

dosing reduces OHSS risk in Japanese IVF/ICSI

patients: a randomized controlled trial. Reprod

Biomed Online. 2021;42(5):909–18. Available from:

https://pubmed.ncbi.nlm.nih.gov/33722477/

Arce JC, Larsson P and García-Velasco JA. Establishing

the follitropin delta dose that provides a comparable

ovarian response to 150 IU/day follitropin alfa.

Reprod Biomed Online. 2020;41(4):616–22.

Available

from:

https://pubmed.ncbi.nlm.nih.gov/32819842/

Halim B and Lubis HP. Dual trigger with gonadotropin

releasing hormone agonist and recombinant human

chorionic gonadotropin improves the outcome of

intrauterine insemination. Obstet Gynecol Sci.

;65(2):207–14.

Arce JC, Nyboe Andersen A, Fernández-Sánchez M,

Visnova H, Bosch E, García-Velasco JA, Barri P, de

Sutter P, Klein BM and Fauser BC. Ovarian response

to recombinant human follicle-stimulating hormone:

a randomized, antimüllerian hormone-stratified,

dose-response trial in women undergoing in vitro

fertilization/intracytoplasmic sperm injection. Fertil

Steril. 2014;102(6):1633-1640.e5. Available from:

https://pubmed.ncbi.nlm.nih.gov/25256937/

Haakman O, Liang T, Murray K, Vilos A, Vilos G, Bates

C, Watson AJ, Miller MR and Abu-Rafea B. In vitro fertilization cycles stimulated with follitropin delta

result in similar embryo development and quality

when compared with cycles stimulated with

follitropin alfa or follitropin beta. F&S reports.

;2(1):30–5.

Available

from:

https://pubmed.ncbi.nlm.nih.gov/34223270/

Merviel P, Heraud MH, Grenier N, Lourdel E, Sanguinet

P and Copin H. Predictive factors for pregnancy after

intrauterine insemination (IUI): an analysis of 1038

cycles and a review of the literature. Fertil Steril.

;93(1):79–88.

Available

from:

https://pubmed.ncbi.nlm.nih.gov/18996517/

Cabry-Goubet R, Scheffler F, Belhadri-Mansouri N,

Belloc S, Lourdel E, Devaux A, Chahine H, De

Mouzon J, Copin H and Benkhalifa M Effect of

Gonadotropin Types and Indications on Homologous

Intrauterine Insemination Success: A Study from

Cycles and a Review of the Literature. Biomed

Res Int. 2017;2017:3512784. Available from:

https://pmc.ncbi.nlm.nih.gov/articles/PMC5745683/

Minano J, Hemmings R, Phillips S, Bissonnette F and

Kadoch I. P-788 A proof-of-concept study

evaluating the effect of personalized dosages of

follitropin delta in intra-uterine insemination (IUI):

Personalized IUI Treatment Study (PITS). Hum

Reprod. 2022;37(Supplement_1). Available from:

https://dx.doi.org/10.1093/humrep/deac107.725

Minano Masip J, Kadoch E, Hemmings R, Phillips S,

Bissonnette F and Kadoch IJ. A prospective proof-of

concept trial on the effect of personalized dosages of

follitropin delta in intrauterine insemination. Reprod

Biomed Online. 2024;48(4). Available from:

https://pubmed.ncbi.nlm.nih.gov/38359732/

Yang R, Zhang Y, Liang X, Song X, Wei Z, Liu J, Yang

Y, Tan J, Zhang Q, Sun Y, Wang W, Qian W, Jin L,

Wang S, Xu Y, Yang J, Goethberg M, Mannaerts B,

Wu W, Zheng Z and Qiao J Comparative clinical

outcome following individualized follitropin delta

dosing in Chinese women undergoing ovarian

stimulation for in vitro fertilization /intracytoplasmic

sperm injection. Reprod Biol Endocrinol. 2022;20(1).

Available from: https://pubmed.ncbi.nlm.nih.gov/36195924/

Refbacks

  • There are currently no refbacks.